Glioma Panel

What is Glioma Panel test?

Glioma Panel is a focused molecular test set that evaluates three cornerstone biomarkers in diffuse gliomas: 1p/19q codeletion, IDH1/2 mutations, and MGMT promoter methylation, to refine diagnosis, prognosis, and treatment planning in line with modern integrated classifications.

Why consider Glioma Panel test in Kottayam?

• Improves diagnostic accuracy beyond histology by distinguishing oligodendroglioma from astrocytoma and stratifying glioblastoma biology, which impacts prognosis and therapy choices.

• Provides predictive information: MGMT promoter methylation is associated with better response to alkylating chemotherapy (e.g., temozolomide), particularly relevant in high‑grade and elderly glioma settings.

Who should get tested for Glioma Panel test in Kottayam?

• Patients with newly diagnosed diffuse gliomas or glioblastoma where integrated histo‑molecular classification is needed to guide management and clinical trial eligibility.

• Patients with limited prior profiling or recurrent tumors where clarifying IDH status, confirming 1p/19q, and establishing MGMT methylation can influence second‑line strategies.

More Information about Glioma Panel test in Kottayam

OTHER NAMES: Glioma Core Molecular Panel, Glioma Marker Panel, glioma panel, brain tumor panel, glioma molecular panel, idh mgmt 1p19q panel, cns tumor profiling, brain tumor molecular test

Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.